Viral Vector Demand Presents A Significant Opportunity

Due to increased clinical trial activity, growing needs for scalable manufacturing processes, and backlogged viral vector manufacturers, Lentivirus and AAV manufacturing present a significant opportunity for potential outsourced service expansion. The availability of funding for cell and gene therapy development and potential applications in novel drug delivery is rapidly expanding. The global Viral Vector/Plasmid DNA Manufacturing market is expected to grow at a 18.8% CAGR through 2028, taking the global market from $2.2B to $8.6B. Factors driving this market growth are the rising prevalence of genetic disorders, cancer, and infectious diseases.